StrategyDecision frameworkPortfolio planning

Patent monetization strategies: choosing and sequencing

By Ipiry TeamPublished August 26, 20267 min read

Short answer

Choosing a monetization route depends on four things: whether anyone practises the claims, how much term remains, whether you can fund enforcement, and whether you need certainty or upside. Strategy is also sequential — routes open and close over a patent's life, and the largest error is letting a fee deadline arrive before deciding, because that leaves only paying or lapsing.

Patent monetization strategies are less about picking the highest-value route than about picking one while several are still available.

Options close over time. Continuations become impossible at grant. Buyers lose interest below three years of term. A fee deadline arriving leaves paying or lapsing.

Which makes timing part of the strategy, not an operational detail attached to it.

Four questions decide the route, and the first one eliminates most of the field.

The four questions

#	Question	If no
1	Does anyone practise the claims?	Selling, licensing and enforcement all weaken sharply
2	How much term remains?	Under 3 years, buyers discount heavily
3	Can you fund enforcement?	Assertion is not available as leverage
4	Certainty or upside?	Sale versus licensing

Question one is the gate. A patent nobody infringes has no licensee, no buyer motivated by risk, and nothing to enforce.

Answer it with a search, not an assumption. Screening for products practising the claims is free and it is the single most informative thing you can do. See patent infringement search.

Matching route to situation

Your situation	Route
You sell a product using it	Practise; mark products
Competitors practise it; you have funding	Enforce or license from strength
Competitors practise it; no funding	Sell
Someone wants to use it, you want ongoing income	License
Different applications, different partners	Field-of-use licences
Mutual exposure with a competitor	Cross-licence
Nobody practises it, term is short	Sell if possible, else release
Covers a discontinued product	Sell or release

"Sell" appears where funding is the constraint, which is the ordinary position for individuals and small companies.

A threat you cannot execute weakens every negotiation. Converting it into an asset someone else can enforce is usually worth more than holding it.

Strategy is sequential

Phase	Available	Closing
Pending	Shape claims, file continuations	—
At allowance	Last continuation window	Closes at issue, no reminder
Years 0–3 after grant	Watch the market, gather evidence	—
First fee, 3.5 yrs	All routes	—
Years 4–7	Evidence of use emerges	—
Second fee, 7.5 yrs	All routes	Term shortening
Years 8–11	Sale window narrowing	—
Third fee, 11.5 yrs	Sell or release, mostly	Buyers thin out
Final years	Practise or release	Sale largely gone

The continuation window is the most valuable and most commonly missed. It lets you write claims aimed at what competitors actually built, and nothing prompts you before it closes.

Evidence of use arrives on the market's schedule, not yours. A patent with no identifiable infringer at year three may have two by year seven.

Certainty versus upside

	Sell	License
Payment	Single, certain	Stream, uncertain
Expected total	Usually lower	Usually higher
Maintenance fees	End	Continue
Enforcement duty	Ends	Yours
Validity risk	Ends	Yours
Administration	Ends	Ongoing
Effort after closing	None	Substantial

Compare against releasing, not against zero. Holding costs money, so a licensing stream barely exceeding the fees is not obviously better than a sale.

Validity risk transferring matters more than it looks. A licensee can pay and challenge validity simultaneously, so a royalty stream is never fully settled while you still own the patent.

The costs any strategy carries

Fee	Due after grant	Large	Small	Micro
First	3.5 years	$2,150	$860	$430
Second	7.5 years	$4,040	$1,616	$808
Third	11.5 years	$8,280	$3,312	$1,656
Total		$14,470	$5,788	$2,894

Ipiry Patent Survival Curve v1.0	Rate
Survive the 3.5-year fee (2022 cohort)	85.8%
Survive the 7.5-year fee (2018 cohort)	64.6%
Reach full term (2014 cohort)	41.4%
Abandoned before full term	58.6%
Conditional: paid first two, pay third	63.0%

Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.

The third fee is where strategy is tested. More than a third of patents whose owners already funded two windows are released at the third, because $8,280 against eight remaining years forces the question properly.

Portfolio strategy is segmentation

Segment	Test	Strategy
Core	Practised, enforced, or blocking	Keep, mark, monitor
Defensive	Covers what a specific opponent does	Keep while relevant
Licensed	Generating income above cost	Keep, audit
Dormant	Nobody practises the claims	Sell or release
Legacy	Covers a discontinued product	Sell or release

Dormant is the largest segment in most portfolios and the least examined, because nothing about a dormant patent demands attention until a fee falls due.

Test defensive rationales specifically. Applied portfolio-wide without naming an opponent, they justify holding everything forever. See patent portfolio.

Foreign members need a different clock

	US	Most other jurisdictions
Fee events	3	Annual
Escalation	Three steps	Every year
Decisions per patent	3	Up to 20
Typical pruning order	Later	Earlier

Foreign members face the question annually, which is why they get released first even where the technology is the same.

Decide by revenue and manufacturing, jurisdiction by jurisdiction. See patent annuity fees by country.

Worked example: three patents, one review

A company reviews three assets 14 months before their fee windows.

	Patent A	Patent B	Patent C
Term remaining	11 yrs	8 yrs	3 yrs
Anyone practising?	Yes, 2 products	No	No
Company practises it?	Yes	No	No
Next fee	$1,616	$3,312	$3,312
Evidence documented?	Chart built	—	—
Funding for enforcement	No	No	No

	Strategy chosen
A	Keep and mark. Core to a shipping product; chart supports a later licence
B	Sell. No internal use, no infringers found, but 8 years is saleable
C	Release. 3 years left, no use, $3,312 against nothing

What the 14 months bought


Patent B sale process	Completed before the deadline
Patent C	Released deliberately, not lapsed by surprise
Patent A	Marking implemented, damages clock started

Patent C is the honest case. Three years and no infringers means release, and there is nothing wrong with that outcome.

Patent B is what the timing bought. At six weeks out it would have joined C.

The decision points that close options

Point	Closes
Parent issues with nothing pending	Continuations, permanently
Term falls below ~3 years	Most buyers
Grace period expires	Everything
Public disclosure before foreign filing	Foreign rights
Assignment left unrecorded	Sales, until fixed

Recorded ownership is the quiet one. A gap discovered during a transaction stalls or kills it, and fixing it can require documents and parties that no longer exist. See assignment search.

Building the review

Step	Timing
1. List every fee due in the next 18 months	Q1
2. Verify entity status and recalculate	Same
3. Screen for products practising each patent	Free
4. Segment into core / defensive / licensed / dormant	Same
5. Start any sale process	Immediately for dormant assets
6. Diarise each window as a decision	Not a payment

Phrase calendar entries as decisions. "Pay $3,312" produces a payment; "decide: keep, sell, license or release" produces a decision.

Patent monetization strategies: the checklist

Answer whether anyone practises the claims first. It gates everything.
Screen with a free search, never an assumption.
Match route to constraint — funding usually decides against enforcement.
Compare each route against releasing, not against zero.
File continuations while the window is open. It closes at issue with no reminder.
Segment portfolios; decide per segment, not per patent.
Test defensive rationales against a named opponent.
Prune foreign members earlier. Annual escalation forces it.
Keep recorded ownership clean before you need it.
Start twelve months out. Late decisions have already lost most of the options.

Common questions

How do I choose a monetization strategy?

Start with whether anyone practises the claims, since that determines whether selling, licensing or enforcement are available at all. Then assess remaining term, your funding capacity, and whether you need certainty now or maximum total over time.

Does strategy change over a patent's life?

Substantially. Early on, continuations can still be filed and coverage shaped. Mid-life, evidence of use may emerge as competitors launch. Late, remaining term falls below what buyers want and options narrow to paying or releasing.

Should I license or sell?

Licensing gives a larger uncertain total and keeps every ongoing cost with you. Selling gives certainty now and ends the fees, enforcement duty and validity risk. Choose by whether you can carry the administration and the risk.

What if I cannot fund enforcement?

Then enforcement is not a strategy, and pretending otherwise weakens every negotiation. Selling to a party who can enforce, or licensing on reasonable terms, converts a threat you cannot execute into value you can collect.

When is the best time to sell?

While meaningful term remains and before a fee deadline forces the decision. Buyers discount heavily below roughly three years remaining, and the process takes months, so twelve months of runway is the practical minimum.

How does portfolio strategy differ from single-patent strategy?

A portfolio can be segmented — core assets kept, defensive ones held while relevant, dormant ones sold or released. That segmentation is the strategy. A single patent gets one decision, made repeatedly at each fee window.

Should I file continuations for monetization reasons?

It is one of the strongest levers available. A continuation lets you write claims aimed at what competitors actually built once that becomes visible, and the window closes permanently when the parent issues with nothing pending.

What signals that a patent should be released?

Nobody practises the claims, no licensee has emerged, remaining term is short, the next fee is substantial, and no buyer has shown interest. Release is a rational outcome, and it should be a decision rather than a lapse.

Does defensive value justify holding?

Only where the claims cover what a likely opponent actually does. Defensive rationales applied portfolio-wide, without testing that, tend to justify holding everything indefinitely at escalating cost.

How do I value the options against each other?

Compare each route's expected net against the alternative of releasing, not against zero. Holding costs money, so a licensing stream barely exceeding the fees is not obviously better than a sale that ends them.

What is the most common strategic error?

Deciding too late. A patent sold before a fee deadline is worth something and the same patent afterwards is worth nothing, so a review conducted in the final weeks has already eliminated most of the options.

Should strategy differ for foreign family members?

Yes, because annuities are annual and escalate every year rather than three times. Foreign members typically face the keep-or-release question earlier and more often, which is why they are usually pruned first.

Patent monetization: the routes available

The ways a patent can generate value — practising, selling, licensing, enforcement, defensive use and deliberate lapse — and what each costs, returns and requires.

Patent portfolio: how one is structured

What a patent portfolio actually is — families and continuations, jurisdictional layers, core versus peripheral rights, and how the structure determines what it is worth.

Intellectual property valuation beyond patents

How IP valuation differs by right type — patents, trademarks, copyright and trade secrets — the three standard approaches, and why the same method gives different answers.

What is your patent worth?

Free AI valuation in 60 seconds, benchmarked against 652,000 KPSS patent value records and the Ipiry Patent Survival Curve.

Value My Patent Free →Takes 60 seconds. No credit card required.